Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.65 |
| ▸ | DRD4 | P21917 | 9/20 | 0.65 |
| ▸ | DRD3 | P35462 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073066 | 0.85 | DRD2 (0.57) | DRD2DRD4DRD3NPC1ALDH1A1 | |
| SCHEMBL23067930 | 0.82 | DRD2 (0.92) | DRD2DRD4DRD3NPC1KDM4E | |
| SCHEMBL5073531 | 0.81 | DRD4 (0.57) | DRD2DRD4DRD3NPC1ATM | |
| SCHEMBL1547986 | 0.81 | DRD4 (0.62) | DRD2DRD4DRD3NPC1HPGD | |
| SCHEMBL5075721 | 0.81 | DRD2 (0.59) | DRD2DRD4DRD3NPC1ALDH1A1 | |
| Formic Acid SCHEMBL5075583 | 0.81 | MTNR1A (0.57) | DRD2DRD4DRD3NPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8053903 | 0.80 | DRD2 (0.88) | DRD2DRD4DRD3NPC1ATM | |
| SCHEMBL5075584 | 0.80 | DRD2 (0.60) | DRD2DRD4DRD3NPC1ALDH1A1 | |
| SCHEMBL9808662 | 0.79 | DRD2 (0.55) | DRD2DRD4DRD3NPC1HPGD | |
| Hydrochloric Acid SCHEMBL8042240 | 0.79 | DRD2 (0.92) | DRD2DRD4DRD3NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | DRD2 4559/4885DRD4 3810/4885DRD3 4256/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | DRD2 4869/4885DRD4 4857/4885DRD3 4856/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | DRD2 4869/4885DRD4 4857/4885DRD3 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.